J&J said it “thanks Dr. Mammen for his contributions” and that William Hait, MD, PhD, will serve as the interim replacement for Dr. Mammen, who held the role for five years.
Before joining J&J, Dr. Mammen worked in executive roles at several pharmaceutical research and development companies, including Merck, Theravance Biopharma, Innoviva and Theravance, according to his LinkedIn profile.
